Impact of Late Lumen Loss on Clinical Outcomes of Side-Branch Bifurcation Lesions Treated by Drug-Coated Balloon Angioplasty With Main-Branch Stenting

Cardiovasc Revasc Med. 2022 Aug:41:92-98. doi: 10.1016/j.carrev.2021.12.020. Epub 2021 Dec 29.

Abstract

Background: Drug-coated balloon (DCB) angioplasty for side branches with main branch stenting is effective for bifurcation lesions and reduces late lumen loss (LLL) in side branches. However, the predictors and clinical implications of LLL after DCB angioplasty are largely unexplored.

Methods: Among 181 patients undergoing DCB angioplasty for side branches with drug-eluting stent implantation for main branches between 2016 and 2018, we enrolled 138 patients (138 lesions) undergoing follow-up coronary angiography within 1 year. The 1-year cumulative rates of target lesion revascularization (TLR) and major adverse cardiac events (MACE: defined as a composite of all-cause death, myocardial infarction, and TLR) were compared between patients with late lumen gain (LLG) (LLG group) and those with LLL (LLL group).

Results: The binary restenosis rate of the side branch was 8.0% (11 lesions), mean LLL was -0.14 ± 0.43 mm, and LLG was observed in 99 lesions (71.7%). The DCB size/reference vessel diameter ratio showed mild discrimination (area under the curve, 0.60; 95% confidence interval, 1.2-65.0; p = 0.03) for predicting the side branch progression. The 1-year cumulative rates of MACE and TLR were not significantly different but numerically lower in the LLG group than in the LLL group (2.0% vs. 7.8%, p = 0.11 and 2.0% vs. 7.7%, p = 0.11, respectively). Lumen regression after DCB angioplasty for side branches are associated with improved clinical outcomes.

Conclusions: The DCB size relative to the reference vessel diameter is a predictor of late lumen enlargement in side branches.

Keywords: Bifurcation lesion; Drug-coated balloon; Percutaneous coronary intervention.

MeSH terms

  • Angioplasty, Balloon* / adverse effects
  • Coated Materials, Biocompatible
  • Coronary Angiography / adverse effects
  • Coronary Artery Disease* / complications
  • Coronary Artery Disease* / diagnostic imaging
  • Coronary Artery Disease* / therapy
  • Coronary Restenosis* / diagnostic imaging
  • Coronary Restenosis* / etiology
  • Coronary Restenosis* / therapy
  • Drug-Eluting Stents* / adverse effects
  • Humans
  • Time Factors
  • Treatment Outcome

Substances

  • Coated Materials, Biocompatible